参考文献/References:
[1] Kjerpeseth LJ,Igland J,Selmer R,et al. Prevalence and incidence rates of atrial fibrillation in Norway 2004-2014[J]. Heart,2021,107(3):201-207.
[2] Heijman J,Guichard JB,Dobrev D,et al. Translational challenges in atrial fibrillation[J]. Circ Res,2018,122(5):752-773.
[3] Wu J,Nadarajah R,Nakao YM,et al. Incident cardiovascular,renal,metabolic diseases and death in individuals identified for risk-guided atrial fibrillation screening:a nationwide cohort study[J]. Open Heart,2023,10(2):e002357.
[4] Lee JS,Han S,Therrien NL,et al. Trends in drug spending of oral anticoagulants for atrial fibrillation,2014-2021[J]. Am J Prev Med,2024,66(3):463-472.
[5] Yue P,Jing S,Liu L,et al. Association between mitochondrial DNA copy number and cardiovascular disease:current evidence based on a systematic review and meta-analysis[J]. PLoS One ,2018,13(11):e0206003.
[6] Liu LP,Cheng K,Ning MA,et al. Association between peripheral blood cells mitochondrial DNA content and severity of coronary heart disease[J]. Atherosclerosis,2017,261:105-110.
[7] Algalarrondo V,Extramiana F. Epidemiology and pathophysiology of atrial fibrillation[J]. Rev Prat,2020,70(8):894-898.
[8] Qian Y,Meng J,Tang H,et al. Different structural remodelling in atrial fibrillation with different types of mitral valvular diseases[J]. Europace ,2010,12(3):371-377.
[9] Du X,Liu T,Shen C,et al. Anti-fibrotic mechanism of SPP1 knockdown in atrial fibrosis associates with inhibited mitochondrial DNA damage and TGF-β/SREBP2/PCSK9 signaling[J]. Cell Death Discov ,2022,8(1):246.
[10] Rababa’h AM,Guillory AN,Mustafa R,et al. Oxidative stress and cardiac remodeling:an updated edge[J]. Curr Cardiol Rev ,2018,14(1):53-59.
[11] Su KN,Ma Y,Cacheux M,Ilkan Z,et al. Atrial AMP-activated protein kinase is critical for prevention of dysregulation of electrical excitability and atrial fibrillation[J]. JCI Insight,2022,7(8):e141213.
[12] Ozcan C,Li Z,Kim G,et al. Molecular mechanism of the association between atrial fibrillation and heart failure includes energy metabolic dysregulation due to mitochondrial dysfunction[J]. J Card Fail,2019,25(11):911-920.
[13] 于佳,李为民. 钙离子通道在心房颤动发病机制中作用研究的进展[J]. 心血管康复医学杂志,2021,30(1):102-104.
[14] Belosludtsev KN,Belosludtseva NV,Dubinin MV. Diabetes mellitus,mitochondrial dysfunction and Ca2+-dependent permeability transition pore[J]. Int J Mol Sci,2020,21(18):6559.
[15] Harada M,Tadevosyan A,Qi X,et al. Atrial fibrillation activates AMP-dependent protein kinase and its regulation of cellular calcium handling:potential role in metabolic adaptation and prevention of progression[J]. J Am Coll Cardiol,2015,66(1):47-58.
[16] Liu M,Liu H,Dudley SC Jr. Reactive oxygen species originating from mitochondria regulate the cardiac sodium channel[J]. Circ Res,2010,107(8):967-974.
[17] Karam BS,Chavez-Moreno A,Koh W,et al. Oxidative stress and inflammation as central mediators of atrial fibrillation in obesity and diabetes[J]. Cardiovasc Diabetol ,2017,16(1):120.
[18] Lai LP,Tsai CC,Su MJ,et al. Atrial fibrillation is associated with accumulation of aging-related common type mitochondrial DNA deletion mutation in human atrial tissue[J]. Chest ,2003,123(2):539-544.
[19] Ren X,Wang X,Yuan M,et al. Mechanisms and treatments of oxidative stress in atrial fibrillation[J]. Curr Pharm Des ,2018,24(26):3062-3071.
[20] Hu L,Wang Z,Carmone C,et al. Role of oxidative DNA damage and repair in atrial fibrillation and ischemic heart disease[J]. Int J Mol Sci,2021,22(8):3838.
[21] Deng J,Jiang Y,Chen ZB,et al. Mitochondrial dysfunction in cardiac arrhythmias[J]. Cells,2023,12(5):679.
[22] Dabravolski SA,Khotina VA,Sukhorukov VN,et al. The role of mitochondrial dna mutations in cardiovascular diseases[J]. Int J Mol Sci,2022,23(2):952.
[23] Roselló-Díez E,Hove-Madsen L,Pérez-Grijalba V,et al. Mitochondrial genetic effect on atrial fibrillation:a case-control study[J]. Mitochondrion ,2021,56:15-24.
[24] Tsuboi M,Hisatome I,Morisaki T,et al. Mitochondrial DNA deletion associated with the reduction of adenine nucleotides in human atrium and atrial fibrillation[J]. Eur J Clin Invest,2001,31(6):489-496.
[25] Lee JS,Ko YG,Shin KJ,et al. Mitochondrial DNA 4977bp deletion mutation in peripheral blood reflects atrial remodeling in patients with non-valvular atrial fibrillation [J]. Yonsei Med J,2015,56(1):53-61.
[26] Vecoli C,Borghini A,Pulignani S,et al. Prognostic value of mitochondrial DNA4977?deletion and mitochondrial DNA copy number in patients with stable coronary artery disease[J]. Atherosclerosis,2018,276:91-97.
[27] Zhao D,Bartz TM,Sotoodehnia N,et al. Mitochondrial DNA copy number and incident atrial fibrillation[J]. BMC Med,2020,18(1):246.
[28] Zajonz T,Koch C,Schwiddessen J,et al. Minimized extracorporeal circulation is associated with reduced plasma levels of free-circulating mitochondrial DNA compared to conventional cardiopulmonary bypass:a secondary analysis of an exploratory,prospective,interventional study[J]. J Clin Med ,2022,11(11):2994.
[29] 叶佛云,吴金强,翟迎港,等. 心房颤动发病机制、预防和治疗研究进展[J]. 山东医药,2021,61(36):100-104.
[30] Xie W,Santulli G,Reiken SR,et al. Mitochondrial oxidative stress promotes atrial fibrillation[J]. Sci Rep,2015,5:11427.
[31] Rocca C,Soda T,de Francesco EM,et al. Mitochondrial dysfunction at the crossroad of cardiovascular diseases and cancer[J]. J Transl Med,2023,21(1):635.
[32] Montaigne D,Marechal X,Lefebvre P,et al. Mitochondrial dysfunction as an arrhythmogenic substrate:a translational proof-of-concept study in patients with metabolic syndrome in whom post-operative atrial fibrillation develops[J]. J Am Coll Cardiol,2013,62(16):1466-1473.
[33] Pool L,Wijdeveld LFJM,de Groot NMS,et al. The role of mitochondrial dysfunction in atrial fibrillation:translation to druggable target and biomarker discovery[J]. Int J Mol Sci,2021,22(16):8463.
[34] Martelli A,Testai L,Colletti A,et al. Coenzyme Q10:clinical applications in cardiovascular diseases[J]. Antioxidants (Basel) ,2020,9(4):341.
[35] Huang H,Darbar D. Gene-guided therapy for catheter-ablation of atrial fibrillation:are we there yet?[J]. J Interv Card Electrophysiol,2016,45(1):3-5.
[36] de Frutos F,Gea A,Hernandez-Estefania R,et al. Prophylactic treatment with coenzyme Q10 in patients undergoing cardiac surgery:could an antioxidant reduce complications? A systematic review and meta-analysis[J]. Interact Cardiovasc Thorac Surg,2015,20(2):254-259.
[37] 裴大军,赵庆彦,Okello E,等. 长期服用辅酶Q10对慢性心力衰竭患者心房颤动发生的影响[J]. 中国心脏起搏与心电生理杂志,2010,24(5):423-425.
[38] Ferro D,Franciosa P,Cangemi R,et al. Serum levels of vitamin E are associated with early recurrence of atrial fibrillation after electric cardioversion[J]. Circ Arrhythm Electrophysiol,2012,5(2):327-333.
相似文献/References:
[1]贺鹏康,周菁.心房颤动治疗新技术——冷冻球囊消融[J].心血管病学进展,2016,(1):1.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.001]
HE Pengkang,ZHOU Jing.Cryoballoon Ablation, A Novel Technology for Atrial Fibrillation Treatment[J].Advances in Cardiovascular Diseases,2016,(4):1.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.001]
[2]都明辉,施海峰*,佟佳宾,等.心房颤动消融相关性无症状性脑缺血[J].心血管病学进展,2016,(1):3.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.002]
DU Minghui,SHI Haifeng*,TONG Jiabin,et al.Silent Cerebral Ischemia Related to Atrial Fibrillation Ablation[J].Advances in Cardiovascular Diseases,2016,(4):3.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.002]
[3]郑环杰,综述,肖骅,等.心房颤动抗栓治疗研究进展[J].心血管病学进展,2016,(2):142.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.012]
ZHENG Huanjie,XIAO Hua.Progress of Antithrombotic Therapy in Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(4):142.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.012]
[4]张清,综述,罗素新,等.新型Xa 因子抑制剂———依度沙班在心房颤动患者抗凝治疗中的研究进展[J].心血管病学进展,2016,(2):151.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.014]
ZHANG Qing,LUO Suxin,TANG Jiong.Novel Factor Xa Inhibitors—Edoxaban in Prevention of Stroke in
Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(4):151.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.014]
[5]许少华,张曼,综述,等.晚钠电流与舒张性心力衰竭[J].心血管病学进展,2016,(2):213.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.030]
XU Shaohua,ZHANG Man,ZHANG Jin,et al.Late Sodium Current and Diastolic Heart Failure[J].Advances in Cardiovascular Diseases,2016,(4):213.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.030]
[6]胡红玲,综述,罗素新,等.预防非瓣膜性心房颤动性脑卒中的治疗新进展[J].心血管病学进展,2016,(3):250.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.009]
HU Hongling,LUO Suxin.New Progress in the Treatment for Cerebral Apoplexy of Nonvalvular
Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(4):250.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.009]
[7]王超,杨国澍,综述,等.关附甲素治疗心房颤动的研究进展[J].心血管病学进展,2016,(3):254.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.010]
WANG Chao,YANG Guoshu,CAI Lin,et al.Research Progress of the Treatment of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(4):254.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.010]
[8]徐小东,综述,杨东辉,等.决奈达隆治疗心房颤动的现状及展望[J].心血管病学进展,2016,(4):368.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.011]
XU Xiaodong,YANG Donghui.Status and Prospect of Dronedarone in Treating Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(4):368.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.011]
[9]张莎,储国俊,吴弘.经导管左心耳封堵术的临床应用进展[J].心血管病学进展,2015,(5):547.[doi:10.3969/j.issn.1004-3934.2015.05.006]
ZHANG Sha,CHU Guojun,WU Hong.Clinial Application Advances in Left Atrial Appendage Closure[J].Advances in Cardiovascular Diseases,2015,(4):547.[doi:10.3969/j.issn.1004-3934.2015.05.006]
[10]汪俊,杨浩.心房颤动射频消融的术式演变[J].心血管病学进展,2015,(5):574.[doi:10.3969/j.issn.1004-3934.2015.05.013]
WANG Jun,YANG Hao.Evolution of Radiofrequency Ablation of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2015,(4):574.[doi:10.3969/j.issn.1004-3934.2015.05.013]
[11]孙静美 尹德春 曲秀芬.炎症信号与心房颤动[J].心血管病学进展,2020,(1):31.[doi:10.16806/j.cnki.issn.1004-3934.2020.01.009]
SUN Jingmei,YIN Dechun,QU Xiufen.Inflammatory Signals Associated with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2020,(4):31.[doi:10.16806/j.cnki.issn.1004-3934.2020.01.009]